AB0753 EFFICACY AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH VASCULITIS
J. Luo,Q. Y. Su,Q. Li,Y. Zhang,X. Y. Li,X. Zhang,Y. Ren,Q. Yu,P. F. He,X. Li,S. X. Zhang
DOI: https://doi.org/10.1136/annrheumdis-2023-eular.4347
IF: 27.973
2023-01-01
Annals of the Rheumatic Diseases
Abstract:Background Vasculitis is characterized by inflammation of blood vessels, leading to potential long-term sequelae, including vision loss, aneurysm formation, and kidney failure. Large vessel vasculitis encompasses Takayasu arteritis and giant cell arteritis, which cause inflammation of the aorta and its major branches. Tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor, has been associated with rapid induction and maintenance of remission in patients with vasculitis. Objectives This study aimed to systematically evaluate the efficacy and safety of tocilizumab therapy in vasculitis. Methods Eight databases (PubMed, Web of Science, Embase, Cochrane Library, Web of Knowledge, MEDLINE, Clinical Trials.gov, and FDA.gov) were searched for studies on tocilizumab treatment of vasculitis published from the date of establishment of the database to January 1, 2023. We used Stata 12.0 software to conduct a meta-analysis of the efficacy and safety of tocilizumab in patients with vasculitis using a random effect model. Results A total of 8 studies with a total of 823 patients were included. Either doses 162mg/week or 8mg/kg/4weeks, compared with placebo, tocilizumab significantly both promoted remission of vasculitis(RR=0.909, 95%CI: 0.768-1.075, P<0.001; RR=0.639, 95%CI: 0.410-0.994, P<0.042)(Figure 1A). No significant difference was observed in the probability of disease relapse in subgroup analysis based on different diseases(Figure 1B). In subgroup analysis based on dose, 8mg/kg/4 weeks doses significantly reduced the probability of disease relapse (RR=0.639, 95% CI: 0.410-0.994, P=0.047)(Figure 1C). The results of subgroup analysis about the rate of adverse events (AE) and serious adverse events (SAE) according to different diseases and different doses, our meta-analysis found that there was no statistical significance between tocilizumab and placebo(Figure 1E-H). It demonstrated the safety of tocilizumab therapy in vasculitis treatment. Conclusion Tocilizumab treatment was effective and well-tolerated in vasculitis patients. Acknowledgements This work was supported by the National Natural Science Foundation of China (No. 82001740). Disclosure of Interests None Declared.